New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Ake vs SLU-PP-332

Syn-Ake vs SLU-PP-332

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Ake
Recovery & RepairFat Loss & Metabolic
SLU-PP-332
Summary
Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
Half-Life
Not applicable (topical; effect duration hours)
Not established in humans; rodent pharmacokinetics suggest hours
Admin Route
Topical
Oral (research), Subcutaneous (research)
Research
Typical Dose
0.01–0.1% (4–8 mg/g in clinical studies)
Not established for humans; rodent studies used ~100 mg/kg/day
Frequency
Twice daily
Once daily in rodent studies
Key Benefits
  • Reduces depth of dynamic wrinkles and expression lines
  • Reversible muscle-relaxing effect on facial muscles
  • Smooths forehead lines, crow's feet, and frown lines
  • Non-invasive alternative to injectable neurotoxins
  • Rapid onset relative to collagen-stimulating peptides
  • Well-studied in in vitro and clinical cosmetic trials
  • Significant enhancement of aerobic endurance capacity
  • Increases mitochondrial density and oxidative metabolism in muscle
  • Promotes beneficial shift toward oxidative muscle fiber phenotype
  • Improves cardiac efficiency and cardiovascular fitness markers
  • Potential for obesity, metabolic syndrome, and heart failure treatment
  • Exercise mimetic for populations unable to exercise (disability, frailty, disease)
Side Effects
  • Generally very well-tolerated topically
  • Rare skin sensitivity or contact dermatitis
  • Theoretical neuromuscular effects at systemic doses (not relevant topically)
  • Limited human data; all studies are preclinical (rodent)
  • Unknown cardiovascular effects with long-term or high-dose use in humans
  • Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
  • Off-target effects not fully characterized
Stacks With